237 related articles for article (PubMed ID: 33041673)
1. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US.
Thokala P; Stevenson M; Kumar VM; Ren S; Ellis AG; Chapman RH
Cost Eff Resour Alloc; 2020; 18():41. PubMed ID: 33041673
[TBL] [Abstract][Full Text] [Related]
2. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
[No Abstract] [Full Text] [Related]
3. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
Malone DC; Dean R; Arjunji R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Dabbous O
J Mark Access Health Policy; 2019; 7(1):1601484. PubMed ID: 31105909
[No Abstract] [Full Text] [Related]
5. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis.
Shih ST; Farrar MA; Wiley V; Chambers G
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1296-1304. PubMed ID: 34321343
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia.
Wang T; Scuffham P; Byrnes J; Downes M
J Neurol; 2022 Dec; 269(12):6544-6554. PubMed ID: 35980467
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I
Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
[TBL] [Abstract][Full Text] [Related]
9. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
10. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
[TBL] [Abstract][Full Text] [Related]
11. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
[TBL] [Abstract][Full Text] [Related]
13. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
15. Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
Paracha N; Hudson P; Mitchell S; Sutherland CS
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):69-89. PubMed ID: 34658008
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Blonda A; Barcina Lacosta T; Toumi M; Simoens S
Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
[No Abstract] [Full Text] [Related]
17. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.
Ramjee L; Vurgun N; Ngai C; Patel M; Tremblay G
Clinicoecon Outcomes Res; 2023; 15():213-226. PubMed ID: 37020570
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease.
Boustani M; Doty EG; Garrison LP; Smolen LJ; Belger M; Klein TM; Murphy DR; Burge R; Wall JK; Johnston JA
Clin Ther; 2022 Nov; 44(11):1449-1462. PubMed ID: 36210219
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
